Andrologia 2018 Oct;50(8):e13071
Cignarella A, Mioni R, Sabbadin C, et al
10.1002/cbin.10634 126 MengQ
Pooled analysis reported no significant effect on not only total arrhythmia [RR=0.96, 95% CI (0.96, 1.05), p =0.36] ( Figure 2 ), but also its subtypes atrial fibrillation [RR=0.96, 95% CI (0.86, 1.07), p =0.43] ( Figure 3 ), atrial flutter [RR= 0.82, 95% CI (0.57, 1.19), p =0.30] ( Figure 3 ), atrial tachycardia [RR=0.64, 95% CI (0.20, 2.01), p =0.44)] ( Figure 3 ), sinoatrial node dysfunction [RR=0.74, 95% CI (0.44, 1.25), p =0.26] ( Figure 3 ), ventricular preterm systole [RR=1.42, 95% CI (0.62, 3.26), p =0.41] ( Figure 3 ), second degree AV block [RR=0.96, 95% CI (0.53, 1.72), p =0.88] ( Figure 3 ), complete AV block [RR=0.75, 95% CI (0.49, 1.17), p =0.21] ( Figure 3 ), ventricular fibrillation [RR=1.00, 95% CI (0.50, 2.02), p =1.00] ( Figure 3 ), ventricular tachycardia [RR=1.37, 95% CI (0.91, 2.08), p =0.13] ( Figure 3 ) from treatment with GLP-1RA versus placebo
Designed to support both weight loss and metabolic health, this innovative treatment helps you feel in control of your body againwith results that go beyond the scale
Additional Information Suggested Use: Take 1 daily with food
